The Mental Health Clinician最新文献

Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report 氯胺酮鼻内治疗长冠肺炎精神并发症1例报告

The Mental Health Clinician Pub Date : 2023-10-01 DOI: 10.9740/mhc.2023.10.239

Kaitlyn Baldwin, Annabelle Wanson, Lee-Anne Gilecki, Courtney Dalton, Evyn Peters, Katelyn Halpape

{"title":"Intranasal ketamine as a treatment for psychiatric complications of long COVID: A case report","authors":"Kaitlyn Baldwin, Annabelle Wanson, Lee-Anne Gilecki, Courtney Dalton, Evyn Peters, Katelyn Halpape","doi":"10.9740/mhc.2023.10.239","DOIUrl":"https://doi.org/10.9740/mhc.2023.10.239","url":null,"abstract":"Abstract Background Neuropsychiatric symptoms associated with long COVID are a growing concern. A proposed pathophysiology is increased inflammatory mediators. There is evidence that typical serotonergic antidepressants have limited efficacy in the presence of inflammation. Although ketamine has shown promise in MDD, there is limited evidence supporting the use of ketamine to treat depressive symptoms associated with long COVID. Case Report This case took place on an inpatient psychiatry unit in a Canadian hospital. The patient was admitted with a 10-month history of worsening depression and suicidality following infection with COVID-19. Depressive symptoms and suicidal ideation were assessed throughout treatment using the Montgomery-Asberg Depression Rating Scale (MADRS). Written informed consent was obtained prior to data collection. This patient received 4 doses of intranasal ketamine which resulted in rapid improvement of depressive symptoms and complete resolution of suicidality with no major adverse events. Discussion There is evidence to support long COVID symptoms result from dysregulated inflammatory processes. The presence of inflammation in patients with MDD has correlated to poor outcomes with first-line antidepressants. It has been demonstrated that IV ketamine is associated with decreased inflammatory mediators and proportional decrease in depressive symptoms. Conclusions Intranasal ketamine in this case was effective at treating depressive symptoms and suicidal ideation associated with long COVID. This is consistent with available data that demonstrates ketamine's efficacy in reducing inflammatory mediators associated with neuropsychiatric symptoms. Therefore, ketamine may be a potential therapeutic option to treat long COVID and persistent depressive symptoms.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135408867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review 通过临床医生调查和图表回顾，探索VMAT2抑制剂治疗的迟发性运动障碍患者的现实世界症状影响和幸福感领域的改善

The Mental Health Clinician Pub Date : 2023-10-01 DOI: 10.9740/mhc.2023.10.225

Jonathan M. Meyer, Craig Chepke, Rimal B. Bera, M. Mercedes Pérez-Rodríguez, Leslie Lundt, Ericha G. Franey, Rahul Dhanda, Betsy Benning, Morgan Bron, Chuck Yonan

{"title":"Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart review","authors":"Jonathan M. Meyer, Craig Chepke, Rimal B. Bera, M. Mercedes Pérez-Rodríguez, Leslie Lundt, Ericha G. Franey, Rahul Dhanda, Betsy Benning, Morgan Bron, Chuck Yonan","doi":"10.9740/mhc.2023.10.225","DOIUrl":"https://doi.org/10.9740/mhc.2023.10.225","url":null,"abstract":"Abstract Introduction Two vesicular monoamine transporter 2 (VMAT2) inhibitors are approved in the United States (US) for the treatment of tardive dyskinesia (TD). There is a paucity of information on the impact of VMAT2 inhibitor treatment on patient social and physical well-being. The study objective was to elucidate clinician-reported improvement in symptoms and any noticeable changes in social or physical well-being in patients receiving VMAT2 inhibitors. Methods A web-based survey was offered to physicians, nurse practitioners, and physician assistants based in the US who prescribed valbenazine for TD within the past 24 months. Clinicians reported data from the charts of patients who met the inclusion criteria and were allowed to recall missing information. Results Respondents included 163 clinicians who reviewed charts of 601 VMAT2-treated patients with TD: 47% had TD symptoms in ≥2 body regions, with the most common being in the head or face and upper extremities. Prior to treatment, 93% of patients showed impairment in ≥1 social domain, and 88% were impaired in ≥1 physical domain. Following treatment, among those with improvement in TD symptoms (n = 540), 80% to 95% showed improvement in social domains, 90% to 95% showed improvement in physical domains, and 73% showed improvement in their primary psychiatric condition. Discussion In VMAT2-treated patients with TD symptom improvement, clinicians reported concomitant improvement in psychiatric disorder symptoms and in social and physical well-being. Regular assessment of TD impact on these types of domains should occur simultaneously with movement disorder ratings when evaluating the value of VMAT2 inhibitor therapy.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135406869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of Board Certified Psychiatric Pharmacists on improving urinary tract infection antibiotic appropriateness at an acute psychiatric hospital 精神科执业药师对提高急性精神病院尿路感染抗生素适宜性的影响

The Mental Health Clinician Pub Date : 2023-10-01 DOI: 10.9740/mhc.2023.10.233

Mohammad Adam Hamad, Andrew Williams, Jamie Kneebusch, Niyati Butala

{"title":"Impact of Board Certified Psychiatric Pharmacists on improving urinary tract infection antibiotic appropriateness at an acute psychiatric hospital","authors":"Mohammad Adam Hamad, Andrew Williams, Jamie Kneebusch, Niyati Butala","doi":"10.9740/mhc.2023.10.233","DOIUrl":"https://doi.org/10.9740/mhc.2023.10.233","url":null,"abstract":"Abstract Introduction Urinary tract infections (UTIs) are one of the most common indications for antibiotic use; patients with psychiatric disorders have a greater risk for UTI compared with patients without these disorders. However, there is little guidance on how best to manage antibiotic therapy in psychiatric hospitals. This study assessed the impact of a Board Certified Psychiatric Pharmacist (BCPP)–driven guideline on managing UTI treatment in an acute psychiatric hospital. Methods The guideline was developed by the psychiatric pharmacy team and distributed to internists, psychiatrists, and pharmacists. Preintervention data were assessed for patients admitted between November 30, 2019, and February 23, 2020; postintervention data were assessed from February 25, 2020, to April 24, 2020. All patients ages 13 years and older who were admitted and had orders for an antibiotic to treat a UTI were included in this study. Appropriate UTI management was defined as an appropriate agent, dose, route, and frequency per the treatment guideline. Additionally, the following criteria were to be ordered and assessed to be deemed appropriate: urinalysis, urine culture, complete blood count, basic or complete metabolic panel, temperature, and subjective symptoms. Results Before intervention, 19.0% of antibiotic orders were appropriate; after intervention, 46.7% of antibiotic orders were appropriate (P = .048). Conclusion The implementation of a BCPP-driven treatment algorithm was associated with a significant increase in appropriate antibiotic regimens for the treatment of UTIs in patients admitted to a psychiatric hospital.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135407225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Barriers to access to psychiatric medications in Missouri county jails 密苏里县监狱中获得精神药物的障碍

The Mental Health Clinician Pub Date : 2023-10-01 DOI: 10.9740/mhc.2023.10.200

Jessica K. Burval, Courtney A. Iuppa, Carrie R. Kriz, Shelby E. Lang, Leigh Anne Nelson, Nicole A. Gramlich, Ellie S. R. Elliott, Roger W. Sommi

{"title":"Barriers to access to psychiatric medications in Missouri county jails","authors":"Jessica K. Burval, Courtney A. Iuppa, Carrie R. Kriz, Shelby E. Lang, Leigh Anne Nelson, Nicole A. Gramlich, Ellie S. R. Elliott, Roger W. Sommi","doi":"10.9740/mhc.2023.10.200","DOIUrl":"https://doi.org/10.9740/mhc.2023.10.200","url":null,"abstract":"Abstract Introduction Objectives of this study were to characterize barriers to receiving psychiatric medications for people who are incarcerated, to compare barriers before competency restoration to those after competency restoration, and to characterize psychiatric medication formularies. Methods A survey of county jails in Missouri was completed between October 2021 and February 2022. Survey questions were answered by medical department personnel, nurses, or a person responsible for medication oversight. Formularies were requested. Results Of 97 jails contacted, 51 completed the survey (53%). Most jails allowed patients to supply their own medications and reported they were “often” or “always” able to continue home medications. Inability to provide home medications was frequently attributed to cost. Notably, only 57% of jails were able to provide long-acting injectable antipsychotics (LAIA), 22% charged a fee for administration of medications, and 31% would not adjust medication times based on food requirements. No major differences existed precompetency and postcompetency for any question. Discussion Jail policies varied; thus, medication access for patients should be approached at the individual level. Potential areas to target to improve access are medication administration times, LAIA access, and removal of medication administration fees.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"63 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135407366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports 药物治疗慢性失眠症的疗效和安全性:临床指南和病例报告综述

The Mental Health Clinician Pub Date : 2023-10-01 DOI: 10.9740/mhc.2023.10.244

Alejandro Del Rio Verduzco, Ahva Salari, Parna Haghparast

{"title":"Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports","authors":"Alejandro Del Rio Verduzco, Ahva Salari, Parna Haghparast","doi":"10.9740/mhc.2023.10.244","DOIUrl":"https://doi.org/10.9740/mhc.2023.10.244","url":null,"abstract":"Abstract Introduction Chronic insomnia affects 5% to 10% of the US population, increasing the demand for treatment options and the corresponding research to prove their validity.1 This review compares recommendations from 3 clinical guidelines and summarizes hypnotic medications, including their newly reported side effects not mentioned in the guidelines. In addition, we aim to provide an overview of what pharmacotherapies are available for prescribers and patients. Methods A literature search was conducted for articles published prior to January 10, 2022, and case reports and clinical studies were retrieved from PubMed and Google Scholar. Results Definitive conclusions cannot be drawn regarding the safety and efficacy of medications reviewed; however, trends are apparent. All 3 guidelines included in this review remarked most treatment recommendations as weak except for cognitive behavioral therapy for insomnia, which is effective but not readily available. Furthermore, based on the 15 case reports and 13 clinical studies presented in this review, many of the medications used for treatment of insomnia present safety concerns. Discussion Benzodiazepines and benzodiazepine receptor agonists are commonly used hypnotic agents with the “Z-drugs” having robust data establishing their efficacy for the short-term treatment of chronic insomnia. However, significant adverse effects related to the central nervous system (CNS), including developing tolerance, addiction, CNS depression, and amnesia, remain barriers to their long-term use. In comparison, newer agents present more favorable side-effect profiles although with less established efficacy. Additionally, off-label agents, including antidepressants, antihistamines, and natural supplements, are discussed due to their prominent use.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"46 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135408625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Consumer perception, knowledge, and uses of cannabidiol 消费者对大麻二酚的认知、知识和使用

The Mental Health Clinician Pub Date : 2023-10-01 DOI: 10.9740/mhc.2023.10.217

Cambrey Nguyen, Karen E. Moeller, Michael McGuire, Brittany L. Melton

{"title":"Consumer perception, knowledge, and uses of cannabidiol","authors":"Cambrey Nguyen, Karen E. Moeller, Michael McGuire, Brittany L. Melton","doi":"10.9740/mhc.2023.10.217","DOIUrl":"https://doi.org/10.9740/mhc.2023.10.217","url":null,"abstract":"Abstract Introduction The legalization of cannabidiol (CBD) across the United States, in varying degrees, has made CBD easily accessible to consumers for complementary and medical purposes. However, there is a paucity of scientific evidence on the benefits and risks of commercially available CBD. In the literature, 2 studies have gathered consumer perceptions and attitudes on cannabis products, specifically CBD, using survey-based questionnaires. This study aimed to build on the aforementioned studies in obtaining consumer perception and knowledge of CBD products using a national survey-based questionnaire. Methods Respondents were recruited through an anonymous, nationwide, online survey administered through Qualtrics in the United States from March 28 to April 30, 2021. The survey consisted of demographics, perceived efficacy and safety of CBD, and resources to obtain CBD information. The survey responses were reported using descriptive statistics along with median and interquartile range for the Likert portion. Results A total of 1158 respondents accessed the survey. The median age was 43 and 50% of respondents were female. The uses for CBD included neurological disorders, pulmonary conditions, gastrointestinal disorders, and chronic pain. The most commonly reported safety concern related to taking CBD was anxiety. Participants agreed that CBD is safe when used responsibly for medical use, and social media was the main source used to obtain information about CBD. Discussion Respondents who used CBD for a condition thought it was helpful; however, most of the adverse effects were rated as moderate to severe, requiring medical attention from a health care professional, hospital, or emergency room visit.","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135409045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to comment on the recently published article "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use". 对最近发表的文章 "近期批准的长效注射用第二代抗精神病药物的最新情况：关于其使用的已知和未知 "一文的评论。

The Mental Health Clinician Pub Date : 2023-06-28 eCollection Date: 2023-06-01 DOI: 10.9740/mhc.2023.06.167

Amy M VandenBerg

引用次数: 0

Comment on "An update on recently approved long-acting injectable second-generation antipsychotics: Knowns and unknowns regarding their use". 关于“最近批准的第二代长效注射抗精神病药物的最新情况:关于其使用的已知和未知”的评论。

The Mental Health Clinician Pub Date : 2023-06-01 DOI: 10.9740/mhc.2023.06.165

Daniel Still, Kathy Do, Paul Thompson, Todd Brackins, James McGrory

引用次数: 0

Terbinafine and risperidone drug interaction contributing to clinical changes in a forensic psychiatric patient. 特比萘芬和利培酮药物相互作用对法医精神病患者临床变化的影响。

The Mental Health Clinician Pub Date : 2023-06-01 DOI: 10.9740/mhc.2023.06.159

Jamie Reynolds, Nicole Gramlich

{"title":"Terbinafine and risperidone drug interaction contributing to clinical changes in a forensic psychiatric patient.","authors":"Jamie Reynolds, Nicole Gramlich","doi":"10.9740/mhc.2023.06.159","DOIUrl":"https://doi.org/10.9740/mhc.2023.06.159","url":null,"abstract":"<p><p>Risperidone is a second generation \"atypical\" antipsychotic that exhibits its clinical effects through a combined effort of risperidone and its active metabolite, 9-hydroxyrisperidone (9-OHR), otherwise known as paliperidone. Risperidone is hepatically metabolized by the cytochrome P450 2D6 (CYP2D6) enzyme into 9-OHR. Significant interference with the metabolism of risperidone may lead to clinical consequences for patients via alterations in the ratio of the parent compound and active metabolite. This patient case reports 1 example of how a drug interaction could contribute to delayed response to a medication increase after psychiatric decompensation. A forensic psychiatric patient was transitioned from oral risperidone to risperidone microspheres long-acting injectable and had worsening of symptoms, necessitating an increased dose of the injection. This increase in symptoms may have been prolonged by addition of a CYP2D6 inhibitor, terbinafine. The changes in clinical symptoms correlate with medication concentrations that were drawn before terbinafine was started, during terbinafine therapy, and after terbinafine was discontinued.</p>","PeriodicalId":22710,"journal":{"name":"The Mental Health Clinician","volume":"13 3","pages":"159-162"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/fa/i2168-9709-13-3-159.PMC10337881.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9825866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precipitated withdrawal with kratom use following naltrexone administration. 纳曲酮给药后使用克瑞托姆引起的急性停药。

The Mental Health Clinician Pub Date : 2023-06-01 DOI: 10.9740/mhc.2023.06.155

Courtney Jarka, Kelsey Gregoire

引用次数: 0